Further Tanezumab Studies Halted

Two more clinical trials for Pfizer drug Tanezumab, a biological agent, studied for its effects on preventing inflamamtion and pain in osteparthritis and other pain conditions have been halted due to concerns from the FDA.

The clincial trial specifically designed to treat osteoarthritis patients using the drug Tanzemuab was stopped a few weeks ago due to reports of some patients requiring joint replacement surgeries. Now, the late stage studies for chronic low back pain and nerve damage from diabetes have been stopped as well.

Read the AP article here.